modelIrbesartanAndDiuretics
Extends from Pharmacolibrary.Drugs.ATC.C.C09DA04.
Information
| name: | IrbesartanAndDiuretics | |
| ATC code: | C09DA04 | route: | oral |
| compartments: | 1 | |
| dosage: | 150 | mg |
| volume of distribution: | 53.0 | L |
| clearance: | 1575 | mL/h |
| other parameters in model implementation | ||
Irbesartan in combination with diuretics (commonly hydrochlorothiazide) is a prescription medication used primarily for the treatment of hypertension. Irbesartan is an angiotensin II receptor antagonist, while the diuretic component reduces fluid volume. This combination is approved and currently used to lower blood pressure and reduce the risk of cardiovascular events.
Pharmacokinetics
Pharmacokinetic parameters estimated based on published data for individual components (irbesartan and hydrochlorothiazide), as no population PK model reporting parameters for the fixed combination product was identified. Parameters mainly reflect healthy adult subjects after single oral administration of the combination.
References
Sherazi, AW, et al., & Rasool, MF (2024). A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide. Therapeutic drug monitoring 46(3) 309–320. DOI:10.1097/FTD.0000000000001141 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38176856
Liu, J, et al., & ShenTu, J (2015). Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers. International journal of clinical pharmacology and therapeutics 53(7) 573–581. DOI:10.5414/CP202208 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25828636
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)